Blogs

Latest Blogs

[wd_asp id=2]

Beyond Weight Loss: How Incretins Are Redefining Obesity Drug Development

Incretin therapies are changing obesity treatment. Discover why future obesity drug development will be defined by outcomes beyond weight loss.…

The Silence of the Genes: Unlocking Antisense Oligonucleotide Therapies for the Renin-Angiotensin-Aldosterone System

The field of gene therapy is rapidly evolving, with antisense oligonucleotide therapies emerging as powerful tools for modulating gene expression.…

From Signals to Systems: Olink Proteomics as a Cornerstone of Synexa’s Biomarker Strategy

We have entered a new era of modern science, where therapeutic innovation is reshaping the field of medicine.…

GMP Grade Ligand Binding and Potency Assays – Frequently Asked Questions

Good Manufacturing Practice ligand binding and potency assays are essential for ensuring the quality, safety, and regulatory compliance of biopharmaceutical…

Validating Immunity: How ELISpot Data Shaped the AELIX-003 HIV Cure Trial

We are proud to share our laboratory’s role in a landmark clinical study published in Nature Communications, titled “Safety, immunogenicity…

From Pathways to Proof: Targeted Phosphoproteomics and PTM Analysis with LC-MS/MS

Quadrupole mass spectrometry (LC-MS/MS) has long established itself as the workhorse of bioanalysis for small molecules, valued for its high…

Establishing Biosimilarity: Regulatory and Scientific Expectations

A biosimilar is defined as a biologic product, highly similar to a reference or originator, with no clinically meaningful differences…